Spelling suggestions: "subject:"drug utilisation"" "subject:"rug utilisation""
41 |
Medicine usage patterns in a district hospital : a therapeutic budget model approach / Margaritha Johanna Eksteen. Part 2Eksteen, Margaritha Johanna January 2008 (has links)
Thesis (M. Pharm. (Pharmacy Practice))--North-West University, Potchefstroom Campus, 2009.
|
42 |
Prescribing patterns of angiotensin-converting enzyme inhibitors for the period 2001 until 2006 / Lourens Johannes RothmannRothmann, Lourens Johannes January 2007 (has links)
Thesis (M.Pharm. (Pharmacy Practice))---North-West University, Potchefstroom Campus, 2008.
|
43 |
The usage of antidiabetic drugs : a managed care approach / Rianda SteynSteyn, Rianda January 2005 (has links)
"Diabetes mellitus" refers to a spectrum of conditions, which all present with hyperglycaemia as
a common medical finding. Diabetes was once thought of as a single disease, but according to
Setter et a/. (2000:378), it includes a heterogeneous group of disorders that are secondary to
various genetic predispositions and precipitating factors. Type 1 diabetes mellitus (DM)
accounts for 10 to 15% of all cases of diabetes mellitus and is clinically characterised by
hyperglycaemia and a propensity to diabetic keto-acidosis. Its control requires chronic insulin
treatment. Although it may occur at any age, it most commonly develops in childhood or
adolescence and is the predominant type of diabetes mellitus diagnosed before age 30 (Beers
& Berkow, 2004). Type 2 DM is usually the type diagnosed in patients older than 30 years of
age. It is also commonly associated with obesity (Berkow, 1992:1108).
The objective of this study was to review the usage and cost of antidiabetic drugs and to
determine the influence of the pricing regulations on the cost of these drugs. This research can
be classified as retrospective and quantitative. Data were obtained from a prescription claims
database, and the study population consisted of all the antidiabetic prescriptions for the year
1 January 2004 to 31 December 2004. The one-year period was divided into three study
periods, namely January to April, May to August and September to December.
Firstly diabetes mellitus was investigated in order to understand the disease and to determine
the prevalence and treatment thereof. It was found that diabetes mellitus is a heterogeneous
disorder acquired from both genetic and environmental factors and that education for the
general population, and in particular for the patients, is the key to preventing and controlling
diabetes and reducing the complications arising from it.
Secondly managed health care, pharmaco-economics and a drug utilisation review were
investigated in order to understand these concepts. The influence of the South African
Government on health care was discussed, including the new pricing regulations of medicine in
South Africa.
Thirdly, the utilisation patterns of antidiabetic drugs were reviewed, analysed and interpreted. It
was determined that the oral antidiabetic agents are relatively less expensive than the insulins
and that they are prescribed more frequently, and secondly that the biguanides presented
almost half (49.4%, n = 116 138) of all the oral antidiabetic agents. It was also determined that
the average cost of the oral antidiabetic drugs was between 21 .O% and 28.0% lower in 2004
than in 1996 - an indication that, despite inflation, the antidiabetic drugs were less expensive in
2004 than eight years ago in 1996. It was also calculated that the total cost savings in
antidiabetic medication could have been R1 448 682.26 if the lower price of antidiabetic agents
had been implemented during the period January to April. And finally it was also determined
that further substantial "cost savings" could have been possible if all the innovator antidiabetic
products had been substituted for less expensive generic antidiabetic products.
Abstract / Thesis (M.Pharm. (Pharmacy Practice))--North-West University, Potchefstroom Campus, 2006.
|
44 |
Prescribing patterns of asthma treatment in the private healthcare sector of South Africa / Johannes Marthinus de WetDe Wet, Johannes Marthinus January 2013 (has links)
Asthma is a chronic disease of the airways and affects many people regardless of their age,
gender, race and socioeconomic status. Since asthma is recognised as one of the major
causes of morbidity and mortality in people and especially in South Africa, the prescribing
patterns, prevalence and medication cost of asthma in South Africa are saliently important and
need to be investigated.
A non-experimental, quantitative retrospective drug utilisation review was conducted on
medicine claims data of a pharmaceutical benefit management company in a section of the
private health care sector of South Africa. The study period was divided into four annual
time periods (1 January 2008 to 31 December 2008, 1 January 2009 to 31 December 2009,
1 January 2010 to 31 December 2010 and 1 January 2011 to 31 December 2011). The
prescribing patterns and cost of asthma medication were investigated and stratified according
to province, age and gender. Patients were included if the prescriptions which were
provided by the health care practitioners matched the Chronic Disease List (CDL) of South
Africa and the International Classification of Disease (ICD-10) coding for asthma and chronic
obstructive pulmonary disease (COPD). Data analysis was conducted by means of the SAS
9.3® computer package. Asthma patients were divided according to different age groups
(there were five different age groups for this study), gender and geographical areas of South
Africa.
The study indicated a steady increase in the prevalence of asthma patients from 0.82% (n =
7949) in 2008 to 1.18% (n = 15 423) in 2009 and reached a minimum of 0.79% (n = 8554) in
2011. Analysis of the prevalence regarding geographical areas in South Africa suggested
that Gauteng had the highest number [n = 17 696, (0.85%)] of asthma patients throughout
the study period, followed by KwaZulu Natal [n = 8 628, 1.16%)] and the Western Cape [(n = 8513, 0.97%) (p < 0.05)]. The prevalence of asthma in female patients [0.89% (n = 26
588)] was higher than in their male counterparts [0.79% (n = 19 244)] (p > 0.05). The results
showed that asthma was not as common chronic disease in children. The total number of
asthma patients younger than 7 years represented 0.64% (n = 2 909). It was found that
patients over 65 years of age showed the highest prevalence of the five age groups [1.94%
(n = 13 403) (p < 0.05)].
The average number of asthma prescriptions per patient per year was 8.28 (95% CI, 8.16-
8.40) and 5.15 (95% CI, 5.06-5.23) in 2008 and 2011, respectively. The number of asthma
items per prescription varied from 1.55 (95% CI, 1.55-1.56) in 2008 to 1.40 (95% CI, 1.39-
1.40) in 2011.
Medication from the MIMS® pharmacological group (anti-asthmatics and bronchodilators)
was used to identify asthma medication. The top three asthma medication with the highest
prevalence in the study period were the anti-inflammatory inhaler of fluticasone (n = 39 721)
followed by the single item combination product of budesonide/ formoterol (n = 25 121) and
salbutamol (n = 24 296). The influence of COPD on asthma treatment and the costimplication
thereof were investigated. Medication from the MIMS® pharmacological group
(anti-asthmatics and bronchodilators) was used to identify COPD medication. This study
also showed that COPD had an influence in the economic burden of the South African
asthma population.
The cost of medication is responsible for the single largest direct cost involved in the
economic burden of asthma. This study showed that asthma represented 0.88% of the
direct medication cost in the study (excluding hospitalisation and indirect cost). The average
cost per prescription and average cost per asthma item both increased throughout the study
period.
The prescribing patterns for the different medication used in the treatment of asthma were
investigated and recommendations for further research in this field of study were made. / MPharm (Pharmacy Practice), North-West University, Potchefstroom Campus, 2014
|
45 |
The usage of antidiabetic drugs : a managed care approach / Rianda SteynSteyn, Rianda January 2005 (has links)
"Diabetes mellitus" refers to a spectrum of conditions, which all present with hyperglycaemia as
a common medical finding. Diabetes was once thought of as a single disease, but according to
Setter et a/. (2000:378), it includes a heterogeneous group of disorders that are secondary to
various genetic predispositions and precipitating factors. Type 1 diabetes mellitus (DM)
accounts for 10 to 15% of all cases of diabetes mellitus and is clinically characterised by
hyperglycaemia and a propensity to diabetic keto-acidosis. Its control requires chronic insulin
treatment. Although it may occur at any age, it most commonly develops in childhood or
adolescence and is the predominant type of diabetes mellitus diagnosed before age 30 (Beers
& Berkow, 2004). Type 2 DM is usually the type diagnosed in patients older than 30 years of
age. It is also commonly associated with obesity (Berkow, 1992:1108).
The objective of this study was to review the usage and cost of antidiabetic drugs and to
determine the influence of the pricing regulations on the cost of these drugs. This research can
be classified as retrospective and quantitative. Data were obtained from a prescription claims
database, and the study population consisted of all the antidiabetic prescriptions for the year
1 January 2004 to 31 December 2004. The one-year period was divided into three study
periods, namely January to April, May to August and September to December.
Firstly diabetes mellitus was investigated in order to understand the disease and to determine
the prevalence and treatment thereof. It was found that diabetes mellitus is a heterogeneous
disorder acquired from both genetic and environmental factors and that education for the
general population, and in particular for the patients, is the key to preventing and controlling
diabetes and reducing the complications arising from it.
Secondly managed health care, pharmaco-economics and a drug utilisation review were
investigated in order to understand these concepts. The influence of the South African
Government on health care was discussed, including the new pricing regulations of medicine in
South Africa.
Thirdly, the utilisation patterns of antidiabetic drugs were reviewed, analysed and interpreted. It
was determined that the oral antidiabetic agents are relatively less expensive than the insulins
and that they are prescribed more frequently, and secondly that the biguanides presented
almost half (49.4%, n = 116 138) of all the oral antidiabetic agents. It was also determined that
the average cost of the oral antidiabetic drugs was between 21 .O% and 28.0% lower in 2004
than in 1996 - an indication that, despite inflation, the antidiabetic drugs were less expensive in
2004 than eight years ago in 1996. It was also calculated that the total cost savings in
antidiabetic medication could have been R1 448 682.26 if the lower price of antidiabetic agents
had been implemented during the period January to April. And finally it was also determined
that further substantial "cost savings" could have been possible if all the innovator antidiabetic
products had been substituted for less expensive generic antidiabetic products.
Abstract / Thesis (M.Pharm. (Pharmacy Practice))--North-West University, Potchefstroom Campus, 2006.
|
46 |
Prescribing patterns of antiretroviral drugs in the private health care sector in South Africa : a drug utilisation review / Daniël Jacobus ScholtzScholtz, Daniël Jacobus January 2005 (has links)
HIV/AIDS is already the leading cause of death worldwide (Unicef et al., 2004:10) with more than 5
million people out of a total of 46 million South Africans that were HIV positive in 2004, giving a total
population prevalence rate of 11 per cent (Dorrington et al., 2004:1). Many people infected do not have access to even the basic drugs needed to treat HIV-related infections and other conditions (Wikipedia, 2004:3). The relative high price of many of the antiretroviral (ARV) drugs and diagnostics on the other hand are one of the main barriers to their availability in developing countries (Unicef et al., 2004:77). ARV drugs registered in South Africa include the Nucleoside/Nucleotide Reverse Transcriptase Inhibitors (NRTIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) and Protease Inhibitors (PIs) (MCC, 2004:1).
The objective of this study was to review, analyse and interpret the prescribing patterns of antiviral drugs, with special reference to antiretroviral drugs, in the private health care sector in South Africa by using a medicine claims database. A quantitative, retrospective drug utilisation review was performed. The data ranging from 1 January 2001 to 31 December 2001, 1 January 2002 to 31 December 2002, and 1 January 2004 to 31 December 2004 were used, dividing each year into three four-month periods, namely January to April, May to August, and September to December.
It was found that 0.38 per cent (n=1 475 380) for 2001, 0.72 per cent (n=2 076 236) for 2002, and 1.68 per cent (n=2 595 254) for 2004 of all studied prescriptions for the research periods 2001, 2002, and 2004 respectively, contained ARV drugs. ARV drugs constituted 0.33 per cent (n=2 951 326) for 2001, 0.87 per cent (n=4 042 145) for 2002, and 1.92 per cent (n=5 305 882) for 2004 of the total number of medicine items prescribed for the study years 2001, 2002 and 2004 respectively. The total cost of ARV drugs amounted to R4 990 784.29, thus constituting 1.31 per cent of the total cost (R379 708 489) of all medicine items on the database for 2001, increased to R18 235 075.75, thus constituting 3.03 per cent of the total cost (R601 350 325) of all medicine items on the database for 2002, and increased to R34 714 483.64, thus constituting 5.25 per cent of the total cost (R661 223 146) of all medicine items on the database for 2004. It was found that 35.31 per cent (n=5 599) for 2001, 52.68 per cent (n=15 004) for 2002, and 74.27 per cent (n=43 482) for 2004 of all studied antiviral prescriptions for the research periods 2001, 2002, and 2004 respectively, contained ARV drugs. ARV drugs constituted 46.25 per cent (n=21 183) for 2001, 70.20 per cent (n=50 246) for 2002, and 85.87 per cent (n=118 718) for 2004 of the total number of antiviral medicine items prescribed for the study years 2001, 2002 and 2004 respectively. The total cost of ARV medicine items, represented 67.33 per cent (n=R4 990 784.29) during 2001, 84.72 per cent (n=R18 235 075.75) during 2002, and 91.20 per cent (n=R34 714 483.64) during 2004 of the total cost of
all antiviral medicine items claimed through the database (n=R7412577.73 for 2001, n=R21523365.56 for 2002, and n=R38 064 347.38 for 2004).
The average cost per ARV medicine items for 2004 increased from R317.93i190.80 for the period
January to April to R369.2W219.50 for the period May to August, and decreased to R324.79±212.48 for the period September to December and resulted in a cost saving of R41 044.35 for the period May to August versus September to December for the ARV medicine items. The implementation of the pricing regulations could thus be a possible reason for this cost saving, due to fact that the single exit price only came into effect from May 2004.
The weighted average number of ARV medicine items per prescription was 1.75*0.31 for 2001, increased to 2.35±0.03 to 2002 and remained stable on 2.35±0.02 for 2004. It was found that majority of prescriptions contained more combination ARV medicine items than single ARV medicine items, ranging from 6 834 (69.76 per cent; n=9 796) prescriptions containing combination ARV medicine items in 2001 and 32 941 (93.39 per cent; n=35 271) prescriptions containing combination ARV medicine items in 2002 to 98 805 (96.93 per cent; n=101 938) prescriptions containing combination ARV medicine items in 2004.
Lastly, it was perceived that didanosine was the active ingredient with the largest prevalence for all three four-month periods of 2001 and also for the periods January to April and May to August of 2002, whilst efavirenz represented the active ingredient with the largest prevalence for the period September to December of 2002, and also for all three four-month periods of 2004. Didanosine represented the active ingredient with the highest total cost for the period January to April of 2001, whilst the combination of lamivudine/zidovudine represented the active ingredient with the highest total cost for the periods May to August and September to December of 2001, and also for all three-four month periods of 2002 and 2004.
Nelfinavir has the highest average cost for period January to April of 2001, ritonavir for period May to August of 2001, and saquinavir mesylate for period September to December of 2001. Nelfinavir has the highest average cost for all three-four month periods of 2002, while didanosine has the highest average cost for all three four-month periods of 2004. / Thesis (M.Pharm. (Pharmacy Practice))--North-West University, Potchefstroom Campus, 2006
|
47 |
Medicine usage patterns in a district hospital : a therapeutic budget model approach / Margaritha Johanna Eksteen. Part 1Eksteen, Margaritha Johanna January 2008 (has links)
According to the National Drug Policy one of the health services objectives is to ensure the availability and accessibility of essential drugs to all citizens. An economic objective of the same policy is to promote the cost-effective and rational use of drugs (Department of Health, 1996). Currently, there is no system to scientifically determine the usage of medicines in the public sector and whether the current usage is satisfactory enough (John, 2004:2). The World Health Organization states that "good drug supply management is an essential component of effective and affordable health care services globally (World Health Organization, 1998:1). In the South African context, even though the Essential Drug List helps health care professionals to treat diseases in the public sector, it does not prescribe the minimum guidelines for medicine supply systems (Department of Health, 2006a).
The general objective of this study was to develop a therapeutic medicine budget model in a district hospital in the public sector of the North-West Province to control medicine usage. This can be done after analysing the medicine usage patterns and then developing a framework for therapeutic budgeting by evaluating appropriate systems, i.e. the International Code for Disease (ICD-10) classification system, with the therapeutic budget model framework.
Retrospective drug utilisation of six months (January 2007 until June 2007) was documented. A random sample population of 25% was selected (n = 1 494). After the data collection period of 9 weeks, the actual study population was only 18.67% (only 1 166 of the 1 494 patients files had a medicine history). All the medicine items prescribed were classified in the therapeutic budget model. Patient confidentially was assured by using a unique pin number on the survey form, so that no names of patients or other biographical details were collected from the patient files onto the survey form, which is in line with the requirements of the Ethics Committee approval conditions for the North-West University.
The total number of medicine items dispensed during the study period was 11 768. The average cost per medicine item was R19.36 ± 86.79 for inpatients. The total number of consultations was 3 220. The average number of medicine items per consultation was 3.66 ± 1.98. The total cost of medicine items during the study period was R244 677.11. The average medicine cost per consultation for inpatients was R70.80 ± 177.72.
The top three budget groups according to frequency represented 68.11% of all medicine used according to budget groups. The top three pharmacological groups according to total cost represented 61.68% of the total cost of pharmacological groups. The top three therapeutic codes according to frequency represented 18.75% of all therapeutic codes. The top three ICD-10 codes based on total cost represented 59.35% of all medical conditions diagnosed.
The total hospital budget for 2007 was predicted at R3 276 750.00. Of this budget, 75% was for pharmaceuticals (R2 457 562.50). The total pharmaceutical medicine cost (excluding surgicals) from the study was R224 677.11 (this was for 18.67% of the total patient visits for six months) which can be calculated at R2 406 824.96 for all patients visits in a full year.
The correlation between the actual budget and the projected budget showed a R50 737.54 surplus in the budget of the hospital. A therapeutic budget model can also help in achieving the following:
• Proper preparation and planning of budgetary policies in a phased manner based on scientific evidence;
• Evaluation of budgetary compliance, cost-efficiency of therapy and standard treatment guidelines (STG) / Essential Drug List (EDL) / formulary compliance;
• Better procurement strategies based on demand, expenditure and inventory control; and
• Better delivery and maintenance of quality health care by evaluating operational and clinical policies.
The therapeutic budget model is a more appropriate manner to use in the projections of budgets and medicine usage. The scope of a therapeutic budget model to be implemented in the hospitals in the public sector of the North-West Province seems to be promising. / Thesis (M. Pharm. (Pharmacy Practice))--North-West University, Potchefstroom Campus, 2009.
|
48 |
Medicine usage patterns in a district hospital : a therapeutic budget model approach / Margaritha Johanna Eksteen. Part 2Eksteen, Margaritha Johanna January 2008 (has links)
Thesis (M. Pharm. (Pharmacy Practice))--North-West University, Potchefstroom Campus, 2009.
|
49 |
Aspects of drug usage in a section of the private health care sector of South Africa : A managed health care approach / C. Smit.Smit, Corlee January 2008 (has links)
Background: According to the Council of Medical Schemes of South Africa (CMS, 2007:52), nearly seventeen percent of the total benefits paid during 2006 were for medicine. Medicine is thus a cost-driving contributor to total healthcare financing. There are various factors influencing and driving medicine usage and cost patterns, including inter alia provider preference, therapeutic committees, marketing and cost.
Objectives: The purpose of this study was to identify the top twenty trade name products
according to total cost and prevalence in a section of the private health care sector of South Africa, and to identify cost driving products.
Methodology: A quantitative, retrospective drug utilisation review (DUR) study was performed on computerised medication records (medicine claims data) for two consecutive years (i.e. 2005 and 2006) that were obtained from a South African pharmaceutical benefit management company (PBM). The study population consisted of 1 218358 and 1 259 099 patients for 2005 and 2006 respectively. A total of 19 860 679 and 21 473017 medicine items that were claimed during 2005 and 2006 were included in the review.
Descriptive statistics were used to describe the data, and were analysed using the Statistical
Analysis System® SAS 9.1® programme. The cost prevalence index (CPI), developed by Serfontein (1989:180), was used as an indicator of the relative expensiveness of medicine. Resource- and activity driver products (cost driving products) were identified on the database by calculating the total cost of the product, the CPI of the product as well as the prevalence of the product. Variables for analysis included age, gender, prescriber and provider types.
Resurts and discussion: A total number of 8 522 574 and 9 046 138 prescriptions were analysed, with an average of 2.33 ± 1.56 and 2.37 ± 1.58 items per prescription during 2005 and 2006 respectively. The average cost per prescription for the total database was R222.16 ± R463.13 for 2005 and R226.25 ± R557.49 for 2006. Members had to co-pay an average of
R26.33 ± R102.70 per prescription in 2005 compared to R29.74 ± R103.96 per prescription in
2006. Children under the age of nine accounted for approximately 13% of the total study population, the adolescent age group < 9 and ≥ 19 years) represented 12%, age group three < 19 and ≥ 45 years) represented 38%, age group four < 45 and ≥ 59 years) represented 21% and the geriatric age group (patients older than 59 years) represented 16% of the total study population on the database. About 44% of the study population were male compared to 56% female patients. The top twenty trade name products ranked according to total cost represented about 13% (N=R1 893376 921.00 and N=R2 046 944382.50 in 2005 and 2006 respectively) of the overall medicine cost. The top five trade name products according to total cost for 2005 in descending order were Upitor 1 Omg and 20mg, Fosamax 70mg, Celebrex 200mg and Prexum 4mg. During 2006 the top five trade name products were similar except for Cipralex 10mg in the place of Celebrex 200mg. The CPls for all these products were above one; these products were also all activity drivers. The top twenty trade name products ranked according to prevalence represented about 11% (N=19 860679 and N=21 473074) of the total medicine prevalence for both study periods. The top five trade name products according to prevalence for both years contained Eltroxin 100mcg, Ecotrin 81 mg, Upitor 10mg and Alcophyllex syrup, with Myprodol capsules in 2005 and Mybulen tablets in 2006. Upitor 1 Omg was the only cost driver product in this list. General medical practitioners prescribed the largest quantity of medicine items and represented about 73% of all the medicine items on the database. The medicine prescribed by general medical prescribers accounted for 65% of the overall medicine expenditure on the database. Pharmacies can be seen as the main providers of medicine items. Pharmacies provided approximately 80% of the medicine items and represented over 91% of the total medicine expenditure. Cardiovascular agents were the main pharmacological group that represented the greatest percentage of the total medicine cost, about 19% in both study years. Cardiovascular agents were also positioned 1st according to prevalence and represented about 14% of the overall medicine prevalence in both the study periods.
Conclusions and recommendations: Cost driver products can be seen as the products that
drives medicine expenditure in the managed health care environment, thus driving the total cost of medicine treatment in the private health care sector of South Africa. Through the
implementation of managed health care information- and management instruments medicine
expenditure can be reduced. Recommendations for future research have been made. / Thesis (M. Pharm. (Pharmacy Practice))--North-West University, Potchefstroom Campus, 2009.
|
50 |
Medicine claims in South Africa : an analysis of the prescription patterns of providers in the private health care sector / Carla Ermelinda de FrancaDe Franca, Carla Ermelinda January 2010 (has links)
Due to the fact that the function of dispensing is not the exclusive practice of a single
profession, there is much conflict surrounding the issue: it forms the crux of the pharmacy
profession but it also forms part of doctors’ scope of practice. Separation of the acts of
prescribing and dispensing would prevent the interest of the doctor, who has the potential to
profit from selling medicines, being placed above the interest of the patient. It would,
however, also affect the essential services that many dispensing doctors provide to
pensioners, unemployed patients, those not covered by a medical scheme and those in rural
areas. The implications of doctor dispensing are not clear as conflicting evidence suggests
that dispensing doctors prescribe more medicine items, injections and antibiotics while
preferring certain brand names on the one hand but on the other, evidence shows that
dispensing doctors dispensed less expensive medicines compared to other health care
providers.
The main objective of this study was to analyse the prescribing patterns of dispensing
doctors and other medicine providers in a section of the private health care sector of South
Africa for 2005 to 2008 by using a medicine claims database.
A retrospective drug utilisation review was conducted by extracting data from a medicine
claims database for a four–year period, from 1 January 2005 to 31 December 2008.
The results revealed that dispensing doctors had a lower cost per prescription compared to
other health care providers (R112.66 ± R4.45 vs. R258.48 ± R23.93) and also had a lower
cost per medicine item (R39.62 ± R2.18 vs. R112.43 ± R7.56) for the entire study period from
2005 to 2008. Dispensing doctors provided more items per prescription compared to other
health care providers (2.85 ± 0.05 items vs. 2.30 ± 0.06 items) but other health care
providers claimed more prescriptions per patient per year (7.50 ± 1.15 prescriptions vs. 3.29
± 0.07 prescriptions). A higher percentage of generic medicine items were provided to
patients visiting dispensing doctors. Dispensing doctors treated a majority of patients aged
above 19 to 44 years of age while other health care providers treated a majority of patients
above 59 years of age. Both dispensing doctors and other health care providers treated a majority of female patients and issued a majority of medicine items to treat acute conditions.
The results also revealed that dispensing doctors generally provided relatively inexpensive
medicine items, including generic and innovator items, for female and male patients of all
ages while other health care providers showed the opposite trend and issued relatively
expensive medicine items to these patients. However, when analysing the top twelve
pharmacological groups claimed, dispensing doctors had relatively higher costs compared to
other health care providers for nine of the pharmacological groups (central nervous system,
analgesic, cardio–vascular, ear, nose and throat, dermatological, urinary system, antimicrobial,
endocrine system and cytostatic). The pharmacological groups contributing to the
highest number of medicine items and highest medicine cost contribution were the antimicrobial
group for dispensing doctors and cardio–vascular group for other health care
providers. / Thesis (M.Pharm. (Pharmacy Practice))--North-West University, Potchefstroom Campus, 2011.
|
Page generated in 0.1131 seconds